Related Experiment Video
Updated: May 8, 2025
A Nonsequencing Approach for the Rapid Detection of RNA Editing
Published on: April 21, 2022
Advances in A-to-I RNA editing in cancer
Yi Zhang1,2, Lvyuan Li1,2, Juana Jessica Mendoza1,2
1NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410078, China.
Abstract:
RNA modifications are widespread throughout the mammalian transcriptome and play pivotal roles in regulating various cellular processes. These modifications are strongly linked to the development of many cancers. One of the most prevalent forms of RNA modifications in humans is adenosine-to-inosine (A-to-I) editing, catalyzed by the enzyme adenosine deaminase acting on RNA (ADAR) in double-stranded RNA (dsRNA). With advancements in RNA sequencing technologies, the role of A-to-I modification in cancer has garnered increasing attention. Research indicates that the levels and specific sites of A-to-I editing are significantly altered in many malignant tumors, correlating closely with tumor progression. This editing occurs in both coding and noncoding regions of RNA, influencing signaling pathways involved in cancer development. These modifications can either promote or suppress cancer progression through several mechanisms, including inducing non-synonymous amino acid mutations, altering the immunogenicity of dsRNAs, modulating mRNA interactions with microRNAs (miRNAs), and affecting the splicing of circular RNAs (circRNAs) as well as the function of long non-coding RNAs (lncRNAs). A comprehensive understanding of A-to-I RNA editing is crucial for advancing the diagnosis, treatment, and prognosis of human cancers. This review explores the regulatory mechanisms of A-to-I editing in cancers and examines their potential clinical applications. It also summarizes current research, identifies future directions, and highlights potential therapeutic implications.
Insights
Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by ADAR enzymes, is altered in cancer and impacts tumor progression. Understanding these RNA modifications is key for developing new cancer diagnostics and therapeutics.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- RNA modifications are crucial for cellular processes and linked to cancer development.
- Adenosine-to-inosine (A-to-I) editing is a prevalent RNA modification in humans, catalyzed by ADAR enzymes.
- Altered A-to-I editing levels and sites are observed in various malignant tumors, correlating with tumor progression.
Purpose of the Study:
- To explore the regulatory mechanisms of A-to-I RNA editing in cancer.
- To examine the potential clinical applications of A-to-I editing in cancer diagnosis, treatment, and prognosis.
- To summarize current research, identify future directions, and highlight therapeutic implications of A-to-I editing in cancer.
Main Methods:
- Review of existing literature on A-to-I RNA editing and its role in cancer.
- Analysis of how A-to-I editing influences cancer development through various molecular mechanisms.
- Examination of clinical applications and therapeutic potential.
Main Results:
- A-to-I editing occurs in coding and noncoding RNA regions, affecting cancer-related signaling pathways.
- Mechanisms include non-synonymous mutations, altered dsRNA immunogenicity, miRNA interactions, and effects on circRNAs and lncRNAs.
- Significant alterations in A-to-I editing are associated with tumor progression and patient prognosis.
Conclusions:
- A comprehensive understanding of A-to-I RNA editing is essential for advancing cancer care.
- A-to-I editing presents potential as a biomarker for cancer diagnosis and prognosis.
- Targeting ADAR enzymes or A-to-I editing pathways may offer novel therapeutic strategies for cancer treatment.
Related Concept Videos
02:23RNA Editing
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:27Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
01:43Proofreading